DIRS.INFO The most relevant business & tech news

☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
▼ + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.

Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration

☆ Move over, millennials: Gen Zers are coming for boomers' houses
▼ + stars: | 2024-01-17 | by ( James Rodriguez | ) www.businessinsider.com time to read: +11 min

After all their economic misfortune, they'll still face a turbulent housing market and potentially tens of thousands of dollars' worth of necessary updates to boomers' aging houses. In his 2022 paper, "Who will buy the baby boomers' homes when they leave them? ", Engelhardt argued that mass aging would send ripples through the housing market but fail to push down prices significantly. After that point, demand for home purchases will once again outpace supply as millennials buy more homes and younger generations, like Gen Z and Gen Alpha, file in behind them. The timing of boomers' exit will mostly benefit younger generations, like Gen Z and Gen Alpha, who should find themselves on steadier footing than their predecessors.

Persons: Xers, they've, Zers, they'll, Odeta Kushi, Kushi, Gary Engelhardt, Engelhardt, Issi Romem, Meredith Whitney, Boomers, Gen Zers —, Gen, who've, millennials, boomers, Jessica Lautz, Nicole Bachaud, They've, Redfin, Alpha, they're, Lautz, savvier, Zoomers, James Rodriguez Organizations: millennials, Syracuse University, Boomers, Federal Reserve, Alpha, National Association of Realtors Locations: granny, New York, Los Angeles, Chicago, Dallas

☆ Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval
▼ + stars: | 2023-10-09 | by ( Mariam E Sunny | ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The FDA, in 2019, approved Pfizer's (PFE.N) oral drug tafamidis, sold under the brand names Vyndaqel and Vyndamax, to treat transthyretin amyloid cardiomyopathy in the United States. Alnylam said it will focus on another drug candidate, vutrisiran, an under-the-skin injection in late-stage trials to treat ATTR amyloidosis-related cardiomyopathy. Branded as Amvuttra, vutrisiran is also approved in the U.S. to treat nerve damage in adult patients with hereditary ATTR amyloidosis. William Blair analyst Myles Minter estimates peak U.S. sales of $2.2 billion for vutrisiran as an ATTR cardiomyopathy treatment.

Persons: Andrew Kelly, patisiran, ATTR amyloidosis, Alnylam, Luca Issi, ATTR, William Blair, Myles Minter, Mariam Sunny, Pooja Desai Organizations: Food and Drug Administration, FDA, REUTERS, Alnylam Pharmaceuticals, RBC, Thomson Locations: White Oak , Maryland, U.S, Massachusetts, United States, Bengaluru

☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
▼ + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.

Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru

RBC Capital Markets anticipates that the next quarter could be choppy for stocks, but the firm shared its list of high-conviction names to navigate the volatility. With these concerns in mind, RBC shared a list of high-conviction stocks that it says are well-positioned to offer upside this quarter. Below are 10 of the names: Alnylam Pharmaceuticals and biotech engineering stock Boston Scientific are new additions to RBC's list of high-conviction names. RBC analyst Shagun Singh said Boston Scientific is "positioned to drive consistent double-digit EPS growth," with upcoming device launches and trial data readouts to act as catalysts. On the energy front, RBC named oil company Diamondback Energy as one of its top picks for the quarter.

☆ CRISPR pioneer Feng Zhang is building a secretive new startup to solve gene-editing's biggest problem — getting into more parts of the body
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +6 min

CRISPR pioneer Feng Zhang is building a new gene-editing startup, Insider has learned. CRISPR pioneer Feng Zhang is in the process of launching yet another ambitious gene-editing startup, backed by approximately $200 million from some of biotech's biggest investors, Insider has exclusively learned. Aera was incorporated in September 2021, shortly after Zhang's research was published in Science. Aera is at least the seventh startup Zhang has cofounded, joining a list that includes base-editing biotech Beam Therapeutics, CRISPR company Editas Medicine, and gene-editing startup Arbor Biotechnologies. While the ARC protein seems tailored for brain delivery, Zhang's suite of proteins could reach other organs, Shepherd said.

☆ 'Wages have been rising': The 10 U.S. cities where the typical worker’s pay has gone up most since 2019
▼ + stars: | 2022-10-10 | by ( Gili Malinsky | ) www.cnbc.com time to read: 1 min

"For decades, wages have been rising," says Issi Romem, a fellow at the ADP Research Institute. And as of the last few years, amid the pandemic, "they've been rising more." Wage Growth found salaried workers at every end of the spectrum ― high, median and low ― saw a rise. When it comes to median-income earners, for example, average monthly earnings in the U.S. went from $6,325 in 2019 to $6,753 in 2021, a 6.77% rise. Here are the 10 metro areas with the greatest gains for median-income earners, including their percent gain and average monthly salaries in 2019 and 2021.

Search resuls for: "Issi"

7 mentions found